Mortality and morbidity of acute lung injury and acute respiratory distress syndrome remain
high because of the lack of pharmacological therapies to prevent injury or promote repair …

Background Bone-marrow derived mesenchymal stem cells (MSCs) reduce the severity of
evolving acute lung injury (ALI), but their ability to repair the injured lung is not clear. A study …

Morbidity and mortality have declined only modestly in patients with clinical acute lung injury
(ALI) and acute respiratory distress syndrome (ARDS), despite extensive research into the …

Despite extensive research into the pathogenesis of acute lung injury and the acute
respiratory distress syndrome (ALI/ARDS), mortality remains high at approximately 40 …

Rationale: Mesenchymal stem cells secrete paracrine factors that can regulate lung
permeability and decrease inflammation, making it a potentially attractive therapy for acute …

Although mesenchymal stromal cells (MSCs) have demonstrated beneficial effects on
experimental acute respiratory distress syndrome (ARDS), preconditioning may be required …

Objectives: Mesenchymal stem cells–based therapies have shown promising effects in
experimental acute respiratory distress syndrome. Different mesenchymal stem cells …

Recent in vivo and in vitro work suggests that mesenchymal stem cells (MSC) have anti-
inflammatory properties. In this study, we tested the effect of administering MSC directly into …

Background The potential for mesenchymal stem cells (MSCs) to reduce the severity of
experimental lung injury has been established in several pre-clinical studies. We have …

The acute respiratory distress syndrome (ARDS) is a multifaceted lung disorder in which no
specific therapeutic intervention is able to effectively improve clinical outcomes. Despite an …